Valby, Denmark

Allan Jensen

USPTO Granted Patents = 2 

Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2021-2023

Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Allan Jensen

Introduction

Allan Jensen is a notable inventor based in Valby, Denmark. He has made significant contributions to the field of biotechnology, particularly in the development of modified antibodies for therapeutic applications. With a total of two patents to his name, Jensen's work focuses on addressing neurodegenerative diseases through innovative methods.

Latest Patents

Jensen's latest patents include a modified anti-PD-L1 antibody and methods for treating neurodegenerative diseases. The specifications disclose modified anti-PD-L1 antibodies that abolish Fc-related effector function while enhancing the clearance rate. This approach maintains therapeutic efficacy for neurodegenerative disease modification. The patents also detail nucleic acid sequences and expression constructs that encode these modified antibodies, along with methods for their production. Furthermore, the specifications outline treatment methods that ensure the antibodies are present in the body for a specific duration, allowing for effective treatment while ensuring they are cleared adequately.

Career Highlights

Throughout his career, Allan Jensen has worked with prominent companies in the biotechnology sector. Notable among these are Immunobrain Checkpoint, Inc. and Yeda Research and Development Company. His experience in these organizations has contributed to his expertise in antibody development and therapeutic applications.

Collaborations

Jensen has collaborated with esteemed colleagues, including Ester Yoles and Berit Olsen Krogh. These partnerships have likely enriched his research and development efforts, fostering innovation in his field.

Conclusion

Allan Jensen's contributions to the field of biotechnology, particularly through his patents on modified anti-PD-L1 antibodies, highlight his commitment to advancing treatments for neurodegenerative diseases. His work exemplifies the impact of innovative thinking in addressing complex medical challenges.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…